Author: Editor

In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Tim Blauwkamp, Ph.D., Chief Scientific Officer and co-founder of Karius.Karius, based in Redwood City, CA, has developed a non-invasive liquid biopsy, a blood test, called the Karius Test®. The test is based on next-generation sequencing of microbial cell-free DNA and can rapidly detect pathogens causing serious infections, including those diseases that are difficult to diagnose through conventional methods. The test can identify and quantify over 1,000 clinically relevant pathogens, including bacteria, DNA viruses, fungi, and parasites. The test can be used to identify infections related to complicated and…

In this edition of The Onco’Zine Brief, Peter Hofland, Ph.D., talks with Vince McRuiz and Margo Shoup, MD, FACS.Margo Shoup is a nationally recognized surgical oncologist who specializes in gastrointestinal cancers and sarcomas. She is also the senior vice president, and system chair of the Nuvance Health Cancer Institute, where she provides strategic and clinical leadership for all aspects of Nuvance Health’s cancer services.Vince McRuiz is a patient of Dr. Shoup.In March 2020 just as the COVID-19 pandemic was ramping up in the northeastern United States, Vince was diagnosed with a retroperitoneal sarcoma — a rare abdominal cancer —that develops…

In this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Armon Sharei, Ph.D. Chief Executive Officer of SQZ Biotech, about the development and manufacturing of cell therapies. Traditionally, the foundation of cancer treatment included surgery, chemotherapy, and radiation therapy. But over the last few decades, targeted therapies —drugs that specifically, target molecular changes seen primarily on cancer cells—have become a standard treatment for many cancers. In addition, over the past several years, immunotherapies—therapies that are designed to use the power of a patient’s own immune system to attack cancer, have emerged as a new treatment. One of the…

In this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Cristian Massacesi, MD, Senior Vice President, Head of Late Development Oncology R&D at AstraZeneca and with Jeffrey Skolnik, MD, Vice President, Clinical Development at Inovio Pharmaceuticals about new data and exciting developments both companies are presenting during the 2020 virtual annual meeting of the American Society of Clinical Oncology – ASCO.This year, amidst the SAR-CoV-2 or coronavirus pandemic, the ASCO organization has been hard at work to offer a unique scientific program for oncology professionals, patient advocates, and industry representatives.In the program, Hofland and Massacesi talk about AZD9833,…

In this edition of The Onco’Zine Brief, Peter Hofland talking with Helen Sabzevari, the president of Precigen. Precigen is a biopharmaceutical company dedicated to the discovery and clinical-stage development of the next generation of gene and cell therapies using precision technology. The company is developing novel therapeutic agents that are designed to target the most urgent and difficult diseases in immuno-oncology, autoimmune disorders, and infectious diseases.During the second part of the virtual meeting of the American Association of Clinical Research – AACR – being held June 22 to June 24, 2020, the company presented preclinical results of an investigational drug…

In this episode of The Onco’Zine Brief, Peter Hofland talks with Thorsten Sperber, Global Head Medical Affairs at Immunomedics. Hofland and Sperber talk about sacituzumab govitecan, a novel antibody-drug conjugate. At the time of the interview, the drug was not yet approved, but in the weeks following the interview, the U.S. Food and Drug Administration (FDA) approved sacituzumab govitecan (Trodelvyâ„¢) for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease.Sacituzumab govitecan, previously known as IMMU-132, is Immunomedics’ lead product and the most…

In this episode of The Onco’Zine Brief, Peter Hofland talks with Terri Conneran, a lung cancer survivor and patient advocate. Struggling in the heat and humidity of the summer of 2016, Terri Conneran believed that her asthma was uncontrolled. In August that year, her physician assistant prescribed her a preventive inhaler. That autumn brought the excuse of allergies, plus time for the new inhaler to take effect. By Christmas 2016, nasal congestion, and a heavy feeling chest with shortness of breath it was time to again see her doctor. Hearing fluid in her lungs, an x-ray showed a mass with…

In this episode of The Onco’Zine Brief, recorded during the 42nd San Antonio Breast Cancer Symposium (SABCS) held December 10 – 14, 2019 in San Antonio, Texas, Peter Hofland talks with Susan Rafte, a 25+ year survivor of metastatic breast cancer and patient advocate.In 1994, eight and a half months after birth to her daughter Marika, Susan Rafte, only 30 years old, was diagnosed with stage III ductal carcinoma.While she was pregnant with her daughter, she first felt a lump in her breast. Her doctors attributed the lump to her pregnancies. However, 18 months later, when Rafte pushed for a…

In this edition of The Onco’Zine Brief, recorded during the 42nd San Antonio Breast Cancer Symposium (SABCS), held December 10 – 14, 2019 in San Antonio, Texas, Peter Hofland talks with leading breast cancer experts and patients about metastatic breast cancer and health-related quality of life hrQoL issues including sexual intimacy, bone health and joint pain. In this roundtable, panelists will also discuss liquid biomarkers for disease progression in the metastatic setting.The expert panel includes; David Portman, MD, founder and Chief Executive Officer (CEO) of Sermonix Pharmaceuticals. Portman is a respected Key Opinion Leader (KOL) in the field, presented clinical…

Neal Shore, MD, FACS – LUGPA discusses Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

Neal Shore, MD, FACS – LUGPA discusses Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

Neal Shore, MD, FACS – LUGPA discusses Olaparib for Metastatic Castration-Resistant Prostate Cancer

Neal Shore, MD, FACS – LUGPA discusses Olaparib for Metastatic Castration-Resistant Prostate Cancer

Neal Shore, MD, FACS – LUGPA discusses Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer

Neal Shore, MD, FACS – LUGPA discusses Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer

In this edition of The Onco’Zine Brief Peter Hofland talks with Catherine Ivy, the Founder and President of the Ben & Catherine Ivy Foundation. The Ben & Catherine Ivy Foundation, established in 2005, is the largest non-government organization supporter of brain tumor – including glioblastoma (GBM) – research in the world. To date, the Ivy Foundation has funded clinical trials and basic science in North America, Europe, and Asia.  Glioblastoma, also known as glioblastoma multiforme, is an aggressive type of cancer that can occur in the brain or spinal cord. Glioblastoma forms from cells called astrocytes, that support nerve cells. The…

Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy

Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy

Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy

Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy

Dre Benedetta Guani – University Hospital of Lausanne discusses Histopathologic validation of the sentinel node technique in early-stage cervical cancerASCOhttps://meetinglibrary.asco.org/record/187420/abstract

Dre Benedetta Guani – University Hospital of Lausanne discusses Histopathologic validation of the sentinel node technique in early-stage cervical cancerASCOhttps://meetinglibrary.asco.org/record/187420/abstract

Liv Johannessen, P.h.D.Syros Pharmaceuticals discusses Activity of SY-5609 an oral noncovalent potent and selective CDK7 inhibitor in preclinical models of colorectal cancerhttps://meetinglibrary.asco.org/record/188034/abstractASCO2020

Liv Johannessen, P.h.D. Syros Pharmaceuticals discusses Activity of SY-5609 an oral noncovalent potent and selective CDK7 inhibitor in preclinical models of colorectal cancer https://meetinglibrary.asco.org/record/188034/abstract ASCO2020

Jeff Petty, MD Wake Forest Baptist Health discusses Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelcaâ„¢ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer

Jeff Petty, MD Wake Forest Baptist Health discusses Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelcaâ„¢ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer

Jeff Petty, MD Wake Forest Baptist Health discusses Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelcaâ„¢ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer

Siqing Fu, M.D., Ph.D. MD Anderson Cancer Center discusses Soricimed Announces Resumption of MD Anderson’s Investigator-Initiated Phase 1b Clinical Trial of SOR-C13 https://www.firstwordpharma.com/node/1731315

Siqing Fu, M.D., Ph.D. MD Anderson Cancer Center discusses Soricimed Announces Resumption of MD Anderson’s Investigator-Initiated Phase 1b Clinical Trial of SOR-C13   https://www.firstwordpharma.com/node/1731315

Robert Epstein, MD – Epstein Health, LLC. – discusses Real-world burden of chemotherapy-induced myelosuppression: Results of a U.S. online survey of patients with cancer. https://meetinglibrary.asco.org/record/190476/abstract #ASCO2020

Robert Epstein, MD – Epstein Health, LLC. – discusses Real-world burden of chemotherapy-induced myelosuppression: Results of a U.S. online survey of patients with cancer. https://meetinglibrary.asco.org/record/190476/abstract #ASCO2020

Robert Epstein, MD – Epstein Health, LLC. – discusses Real-world burden of chemotherapy-induced myelosuppression: Results of a U.S. online survey of patients with cancer. https://meetinglibrary.asco.org/record/190476/abstract #ASCO2020

Raj Malik, MD – G1 Therapeutics discusses G1 Therapeutics to present data showing myelopreservation benefits of Trilaciclib in patients with small cell lung cancer at the ASCO20 Virtual Scientific Program. http://investor.g1therapeutics.com/news-releases/news-release-details/g1-therapeutics-present-data-showing-myelopreservation-benefits

Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner Summary: SO-C101 is a IL-15 superagonist being developed for the treatment of advanced solid tumors – currently in an ongoing Phase 1 trial (NCT04234113) – Poster shows new preclinical data detailing anti-tumor efficacy in tumor mouse models – SO-C101 monotherapy significant reduced tumor growth in early and advanced treatment settings – SO-C101 in combination with PD-1 inhibitors led to durable tumor response in a majority of…

Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner Summary: SO-C101 is a IL-15 superagonist being developed for the treatment of advanced solid tumors – currently in an ongoing Phase 1 trial (NCT04234113) – Poster shows new preclinical data detailing anti-tumor efficacy in tumor mouse models – SO-C101 monotherapy significant reduced tumor growth in early and advanced treatment settings – SO-C101 in combination with PD-1 inhibitors led to durable tumor response in a majority of…

Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner Summary: SO-C101 is a IL-15 superagonist being developed for the treatment of advanced solid tumors – currently in an ongoing Phase 1 trial (NCT04234113) – Poster shows new preclinical data detailing anti-tumor efficacy in tumor mouse models – SO-C101 monotherapy significant reduced tumor growth in early and advanced treatment settings – SO-C101 in combination with PD-1 inhibitors led to durable tumor response in a majority of…

Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner Summary: SO-C101 is a IL-15 superagonist being developed for the treatment of advanced solid tumors – currently in an ongoing Phase 1 trial (NCT04234113) – Poster shows new preclinical data detailing anti-tumor efficacy in tumor mouse models – SO-C101 monotherapy significant reduced tumor growth in early and advanced treatment settings – SO-C101 in combination with PD-1 inhibitors led to durable tumor response in a majority of…

Khalil Choucair, MD – The Kansas University School of Medicine discusses Liquid biopsy: A community-based oncology practice experience. #ASCO2020 https://meetinglibrary.asco.org/record/188007/abstract

Khalil Choucair, MD – The Kansas University School of Medicine discusses Liquid biopsy: A community-based oncology practice experience. #ASCO2020 https://meetinglibrary.asco.org/record/188007/abstract

Khalil Choucair, MD – The Kansas University School of Medicine discusses Liquid biopsy: A community-based oncology practice experience. #ASCO2020 https://meetinglibrary.asco.org/record/188007/abstract

Razelle Kurzrock, MD – UC San Diego Health discusses a Comprehensive analysis of HER2 status through genomic, transcription, and translation among 5,305 patients with diverse malignancies.

Razelle Kurzrock, MD – UC San Diego Health discusses a Comprehensive analysis of HER2 status through genomic, transcription, and translation among 5,305 patients with diverse malignancies.

Razelle Kurzrock, MD – UC San Diego Health discusses a Comprehensive analysis of HER2 status through genomic, transcription, and translation among 5,305 patients with diverse malignancies.

Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine and the director of the Cancer Immunotherapeutics Center within the UPMC Hillman Cancer Center Immunology and Immunotherapy Program discusses A phase I, first-in-human, open-label, dose-escalation study of MGD013.

Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine and the director of the Cancer Immunotherapeutics Center within the UPMC Hillman Cancer Center Immunology and Immunotherapy Program discusses A phase I, first-in-human, open-label, dose-escalation study of MGD013.

Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine and the director of the Cancer Immunotherapeutics Center within the UPMC Hillman Cancer Center Immunology and Immunotherapy Program discusses A phase I, first-in-human, open-label, dose-escalation study of MGD013

Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine and the director of the Cancer Immunotherapeutics Center within the UPMC Hillman Cancer Center Immunology and Immunotherapy Program, discusses A phase I, first-in-human, open-label, dose-escalation study of MGD013.

Total glossectomy is a surgical option for patients with advanced (stage IV cancers) or recurrent tongue cancer. Advanced cancer of the tongue has severe repercussions to function and survival of the affected patients. This procedure is most commonly performed for oncologic control. CASE REPORT The patient, a 53-year-old male affected by carcinoma of base of tongue, was referred to Dr. Mathan Mohan. After extensive clinical and laboratory examination, Dr. Mathan nominated the patient for Total Glossectomy (TG) with PMMC flap reconstruction. RESECTION The procedure of total glossectomy for surgical management of such locally advanced cancer of the tongue is always…

Buccal cancer involving masticator space grows rapidly and penetrates well with a high recurrence rate due its aggressive nature. The local recurrence rate is very high, and many patients are treated with palliative intent because of their eventual poor outcome. Results are poor because of inability to achieve negative margins in three dimensions. Also, the surgical clearance is difficult because of the extent of tumour spread in masticator space. Cancers originating from the masticator space, pterygoid plates or skull base, invade adjacent anatomical structures, thus surgical tumour resection becomes very challenging. CASE REPORT The present case describes the surgical management…

Juan Carlos Varela, MD AdventHealth discusses AdventHealth launches first-of-its-kind immunotherapy treatment, clinical trial for specific blood cancer patients.

Juan Carlos Varela, MD – AdventHealth discusses AdventHealth launches first-of-its-kind immunotherapy treatment, clinical trial for specific blood cancer patients

Juan Carlos Varela, MD AdventHealth discusses AdventHealth launches first-of-its-kind immunotherapy treatment, clinical trial for specific blood cancer patients.

Nicolas Poirier, Ph.D. – OSE Immunotherapeutics – discusses Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of Immune Myeloid Cells in Immuno-Oncology and New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform (BiCKI®) and Bifunctional Therapy Targeting PD-1 and IL-7 (BiCKI®-IL-7) For Cancer Immunotherapy – What is the next step for this research?

Nicolas Poirier, Ph.D. – OSE Immunotherapeutics – discusses – Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of Immune Myeloid Cells in Immuno-Oncology and New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform (BiCKI®) and Bifunctional Therapy Targeting PD-1 and IL-7 (BiCKI®-IL-7) For Cancer Immunotherapy.

David A. Reardon, MD Dana-Farber Cancer Institute discusses INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma GBM Interim results. What is the next step for this research?

David A. Reardon, MD Dana-Farber Cancer Institute discusses INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma GBM Interim results. – How will this affect clinicians today?

David A. Reardon, MD Dana-Farber Cancer Institute discusses What is the rationale in combining these agents together? – INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma GBM Interim results.

David A. Reardon, MD Dana-Farber Cancer Institute discusses INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma GBM Interim results.

Nicholas J. Vogelzang, MD Comprehensive Cancer Centers of Nevada discusses CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced prostate cancer and PROCLAIM-CX-072: Analysis of patients with prostate advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab

Christoph Röllig, MD discusses For Acute Myeloid Leukemia, Genetic Testing Is Often Worth the Wait

Andrea Enzinger, MD Dana-Farber Cancer Institute discusses US trends and racial/ethnic disparities in opioid access among patients with poor prognosis cancer near end of life.

Nikhil C. Munshi, M.D of Dana Farber Cancer Institute discusses the positive results from pivotal KarMMa study of Ide-cel in MM Read here: https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-and-bluebird-bio-present-updated-positive

Nikhil C. Munshi, M.D of Dana Farber Cancer Institute discusses the positive results from pivotal KarMMa study of Ide-cel in MM Read here: https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-and-bluebird-bio-present-updated-positive

Nikhil C. Munshi, M.D of Dana Farber Cancer Institute discusses the positive results from pivotal KarMMa study of Ide-cel in MM Read here: https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-and-bluebird-bio-present-updated-positive

Marwan Fakih, MD of City of Hope discusses CodeBreak 100: activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer Read here: https://meetinglibrary.asco.org/record/185490/abstract

Marwan Fakih, MD of City of Hope discusses CodeBreak 100: activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer Read here: https://meetinglibrary.asco.org/record/185490/abstract

Featuring David Gandara, MD and Johannes Kratz, MD Please visit www.oncocyte.com for more information on DetermaRx   2020 has ushered in two important milestones in early-stage lung cancer. First, CMS approved DetermaRx, a molecular test that identifies patients with Stage I-IIA non-squamous NSCLC who are at high risk of recurrence, and may benefit from adjuvant chemotherapy. Second, the ADAURA trial results, presented at ASCO, demonstrated the efficacy of osimertinib in EGFR-positive early-stage NSCLC. In this webinar, we will review these latest research findings as well as ongoing clinical trials on the use of chemotherapy, targeted therapy, and immunotherapy in early-stage…

Sudhir Manda, MD of Arizona Oncology discusses the long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib.

Sudhir Manda, MD of Arizona Oncology discusses the long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib.

Matthew P. Goetz, MD of Mayo Clinic @MayoClinic discusses acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib alone or in combination with endocrine therapy. Read here: https://meetinglibrary.asco.org/record/185090/abstract

Matthew P. Goetz, MD of Mayo Clinic @MayoClinic discusses acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib alone or in combination with endocrine therapy. Read here: https://meetinglibrary.asco.org/record/185090/abstract

Timothy A Yap, MD, PhD of MD Anderson Cancer Center @MDAndersonNews discusses AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors. Read here: https://meetinglibrary.asco.org/record/187808/abstract

Timothy A Yap, MD, PhD of MD Anderson Cancer Center @MDAndersonNews discusses AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors. Read here: https://meetinglibrary.asco.org/record/187808/abstract

Timothy A Yap, MD, PhD of MD Anderson Cancer Center @MDAndersonNews discusses AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors. Read here: https://meetinglibrary.asco.org/record/187808/abstract

Matthew P. Goetz, MD of Mayo Clinic @MayoClinic discusses acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib alone or in combination with endocrine therapy Read here: https://meetinglibrary.asco.org/record/185090/abstract

Caron Jacobson, MD of Dana Farber Cancer Institute @DanaFarber discusses the interim analysis of zuma-5 presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/186013/abstract

Nathan A. Pennell MD @n8pennell of Cleveland Clinic @CleClinicMD @ClevelandClinic discusses a phase I safety and feasibility study of neoadjuvant chemoradiation plus pembrolizumab followed by consolidation pembrolizumab in resectable stage IIIA non-small cell lung cancer. Read here: https://meetinglibrary.asco.org/record/184547/abstract

Nathan A. Pennell MD @n8pennell of Cleveland Clinic @CleClinicMD @ClevelandClinic discusses a phase I safety and feasibility study of neoadjuvant chemoradiation plus pembrolizumab followed by consolidation pembrolizumab in resectable stage IIIA non-small cell lung cancer. Read here: https://meetinglibrary.asco.org/record/184547/abstract

Lipika Goyal, MD of Massachusetts General Hospital @MassGeneralNews discusses the data for futibatinib in advanced intrahepatic cholangiocarcinoma. Read here: https://www.prnewswire.com/news-releases/taiho-oncology-announces-presentation-of-data-for-futibatinib-in-advanced-intrahepatic-cholangiocarcinoma-at-2020-asco-meeting-301068213.html?tc=eml_cleartime

Sagar Lonial, MD @SagarLonialMD of Winship Cancer Institute @WinshipAtEmory discusses ixazomib vs placebo maintenance for NDMM patients not undergoing autologous stem cell transplant. Read here: https://meetinglibrary.asco.org/record/186184/abstract

Sagar Lonial, MD @SagarLonialMD of Winship Cancer Institute @WinshipAtEmory discusses ixazomib vs placebo maintenance for NDMM patients not undergoing autologous stem cell transplant. Read here: https://meetinglibrary.asco.org/record/186184/abstract

Sagar Lonial, MD @SagarLonialMD of Winship Cancer Institute @WinshipAtEmory discusses ixazomib vs placebo maintenance for NDMM patients not undergoing autologous stem cell transplant. Read here: https://meetinglibrary.asco.org/record/186184/abstract

Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH for Richter’s syndrome. Read here: https://meetinglibrary.asco.org/record/186876/abstract

Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH for Richter’s syndrome. Read here: https://meetinglibrary.asco.org/record/186876/abstract

Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH for Richter’s syndrome. Read here: https://meetinglibrary.asco.org/record/186876/abstract

Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission rates in treatment-naïve acute myeloid leukemia patients. https://library.ehaweb.org/eha/2020/eha25th/303390/courtney.dinardo.a.randomized.double-blind.placebo-controlled.study.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Ddinardo

Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission rates in treatment-naïve acute myeloid leukemia patients. https://library.ehaweb.org/eha/2020/eha25th/303390/courtney.dinardo.a.randomized.double-blind.placebo-controlled.study.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Ddinardo

Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission rates in treatment-naïve acute myeloid leukemia patients. https://library.ehaweb.org/eha/2020/eha25th/303390/courtney.dinardo.a.randomized.double-blind.placebo-controlled.study.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Ddinardo

Huma Q. Rana, MD of Dana Farber Cancer Institute @DanaFarber discusses a randomized controlled trial of video-education or in-person genetic counseling for men with prostate cancer (ProGen). Read here: https://meetinglibrary.asco.org/record/187445/abstract

Huma Q. Rana, MD of Dana Farber Cancer Institute @DanaFarber discusses a randomized controlled trial of video-education or in-person genetic counseling for men with prostate cancer (ProGen). Read here: https://meetinglibrary.asco.org/record/187445/abstract

Ryan Hartmaier, PhD of AstraZeneca discusses TATTON (savolitinib + osimertinib) – measuring ctDNA clearance as a potential predictor of PFS in EGFRm MET-amplified NSCLC. https://www.ascopost.com/issues/july-25-2020/ctdna-clearance-predicts-progression-free-survival-with-osimertinibsavolitinib-in-egfr-mutant-met-amplified-nsclc/

Ryan Hartmaier, PhD of AstraZeneca discusses TATTON (savolitinib + osimertinib) – measuring ctDNA clearance as a potential predictor of PFS in EGFRm MET-amplified NSCLC. https://www.ascopost.com/issues/july-25-2020/ctdna-clearance-predicts-progression-free-survival-with-osimertinibsavolitinib-in-egfr-mutant-met-amplified-nsclc/

Philadelphia, PA (July 21, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Oncoceutics’ investigational cancer drug ONC201 for the treatment of “H3 K27M-mutant glioma”.The Rare Pediatric Disease Priority Review Voucher program, which was created as part of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012, is intended to incentivize the development of new therapies for rare pediatric diseases. Should ONC201 be approved by the FDA for H3 K27M-mutant glioma, the Rare Pediatric Disease Designation may enable Oncoceutics…

Ryan Hartmaier, PhD of AstraZeneca discusses TATTON (savolitinib + osimertinib) – measuring ctDNA clearance as a potential predictor of PFS in EGFRm MET-amplified NSCLC. https://www.ascopost.com/issues/july-25-2020/ctdna-clearance-predicts-progression-free-survival-with-osimertinibsavolitinib-in-egfr-mutant-met-amplified-nsclc/

Huma Q. Rana, MD of Dana Farber Cancer Institute @DanaFarber discusses a randomized controlled trial of video-education or in-person genetic counseling for men with prostate cancer (ProGen). Read here: https://meetinglibrary.asco.org/record/187445/abstract

Chadi Nabhan MD, MBA, FACP @chadinabhan of Caris Life Sciences @carisls discusses the characterizations of KRAS mutations in non-small cell lung cancer. Read here: https://meetinglibrary.asco.org/record/184890/abstract

Chadi Nabhan MD, MBA, FACP @chadinabhan of Caris Life Sciences @carisls discusses the characterizations of KRAS mutations in non-small cell lung cancer. Read here: https://meetinglibrary.asco.org/record/184890/abstract

Neelima Denduluri, MD @ndenduluri1 of Virginia Cancer Specialists @VCSpecialists discusses CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e13029

Robert L. Coleman, MD of MD Anderson Cancer Center discusses the phase III randomized controlled trail of SSC followed by platnium-based chemotherapy. Read here: https://meetinglibrary.asco.org/record/161486/abstract

Robert L. Coleman, MD of MD Anderson Cancer Center discusses the phase III randomized controlled trail of SSC followed by platnium-based chemotherapy. Read here: https://meetinglibrary.asco.org/record/161486/abstract

Philadelphia, PA (July 22, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates GBM Awareness Day this July and expresses its support for all those affected by this devastating form of brain cancer. Glioblastoma (GBM) is the most common type of malignant brain tumor among adults and is typically fatal. The two-year survival rate for GBM is less than 20%, and little progress has been made in battling brain cancer over the past 50 years. ONC201, the company’s lead development candidate, is currently being tested in clinical trials for brain cancer, including GBM. Early results for the ONC201 trials…

Robert L. Coleman, MD of MD Anderson Cancer Center discusses the phase III randomized controlled trail of SSC followed by platnium-based chemotherapy. Read here: https://meetinglibrary.asco.org/record/161486/abstract

Alex Spira, MD, PhD of Virginia Cancer Specialists @VCSpecialists discusses PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072 presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/186711/abstract

Alex Spira, MD, PhD of Virginia Cancer Specialists @VCSpecialists discusses CX-2029, a PROBODY drug conjugate targeting CD71: Results from a first-in-human study in patients with advanced cancer presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/185085/abstract

Michael Korn, MD, CMO of Caris Life Sciences discusses the enrichment of alterations in targetable molecular pathways in KRAS wild-type pancreatic cancer. Read here: https://meetinglibrary.asco.org/record/186629/abstract

Elizabeth Swisher, MD of UW Medicine @UWMedicine discusses characterization of patients with long-term responses to rucaparib in recurrent ovarian cancer. Read here: https://meetinglibrary.asco.org/record/185449/abstract

Elizabeth Swisher, MD of UW Medicine @UWMedicine discusses characterization of patients with long-term responses to rucaparib in recurrent ovarian cancer. Read here: https://meetinglibrary.asco.org/record/185449/abstract

Adam Brufsky, MD, PhD of University of Pittsburgh Cancer Institute discusses the MINDACT and HER2 guidelines in genomic profiling for breast cancer. Read here: https://meetinglibrary.asco.org/record/188425/abstract

Adam Brufsky, MD, PhD of University of Pittsburgh Cancer Institute discusses the MINDACT and HER2 guidelines in genomic profiling for breast cancer.

Nancy U. Lin, MD of Dana-Farber Cancer Institute @DanaFarber discusses tucatinib vs. placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases Read here: https://meetinglibrary.asco.org/record/185141/abstract

Nancy U. Lin, MD of Dana-Farber Cancer Institute @DanaFarber discusses tucatinib vs. placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases Read here: https://meetinglibrary.asco.org/record/185141/abstract

Michael Lim, MD of The Johns Hopkins Hospital @hopkinskimmel discusses the phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM. Read here: https://meetinglibrary.asco.org/record/187521/abstract

Michael Lim, MD of The Johns Hopkins Hospital @hopkinskimmel discusses the phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM. Read here: https://meetinglibrary.asco.org/record/187521/abstract

Michael Lim, MD of The Johns Hopkins Hospital @hopkinskimmel discusses the phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM. Read here: https://meetinglibrary.asco.org/record/187521/abstract

Cathy L. Graham, MD of Winship Cancer Institute @WinshipAtEmory discusses basal subtype and clinical estrogen receptor status of genomically basal breast tumors in Caucasian, African American, and Latin American patients. Read here: https://meetinglibrary.asco.org/record/190857/abstract

Cathy L. Graham, MD of Winship Cancer Institute @WinshipAtEmory discusses basal subtype and clinical estrogen receptor status of genomically basal breast tumors in Caucasian, African American, and Latin American patients. Read here: https://meetinglibrary.asco.org/record/190857/abstract

Cathy L. Graham, MD of Winship Cancer Institute @WinshipAtEmory discusses basal subtype and clinical estrogen receptor status of genomically basal breast tumors in Caucasian, African American, and Latin American patients. Read here: https://meetinglibrary.asco.org/record/190857/abstract

Debra Patt, MD, PhD of Texas Oncology discusses driving quality improvement: how clinical decision support can facilitate compliance with evidence-based pathways.

Debra Patt, MD, PhD of Texas Oncology discusses driving quality improvement: how clinical decision support can facilitate compliance with evidence-based pathways. Read here: https://meetinglibrary.asco.org/record/187164/abstract

Debra Patt, MD, PhD of Texas Oncology discusses driving quality improvement: how clinical decision support can facilitate compliance with evidence-based pathways. Read here: https://meetinglibrary.asco.org/record/187164/abstract

William Dale, MD @WilliamDale_MD of City of Hope @CityofHope discusses integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer planned for systemic anticancer therapy. Read here: https://meetinglibrary.asco.org/record/186699/abstract

William Dale, MD @WilliamDale_MD of City of Hope @CityofHope discusses integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer planned for systemic anticancer therapy. Read here: https://meetinglibrary.asco.org/record/186699/abstract

William Dale, MD @WilliamDale_MD of City of Hope @CityofHope discusses integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer planned for systemic anticancer therapy. Read here: https://meetinglibrary.asco.org/record/186699/abstract

Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses phase I/II clinical trial of autologous CMV-specific cytotoxic t-cells for GBM patients https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2014-0899.html

Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses phase I/II clinical trial of autologous CMV-specific cytotoxic t-cells for GBM patients https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2014-0899.html

Mike Thompson, MD, PhD @mtmdphd of Aurora Cancer Care @Aurora_Cancer discusses global rates of influenza and pneumococcal vaccination in multiple myeloma patients in INSIGHT MM: impact on healthcare resource utilization and overall survival. Read here: https://library.ehaweb.org/eha/2020/eha25th/294884/michael.a.thompson.global.rates.of.influenza.28fv29.and.pneumococcal.28pv29.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dinsight

Mike Thompson, MD, PhD @mtmdphd of Aurora Cancer Care @Aurora_Cancer discusses global rates of influenza and pneumococcal vaccination in multiple myeloma patients in INSIGHT MM: impact on healthcare resource utilization and overall survival. Read here: https://library.ehaweb.org/eha/2020/eha25th/294884/michael.a.thompson.global.rates.of.influenza.28fv29.and.pneumococcal.28pv29.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dinsight

Mike Thompson, MD, PhD @mtmdphd of Aurora Cancer Care @Aurora_Cancer discusses global rates of influenza and pneumococcal vaccination in multiple myeloma patients in INSIGHT MM: impact on healthcare resource utilization and overall survival. Read here: https://library.ehaweb.org/eha/2020/eha25th/294884/michael.a.thompson.global.rates.of.influenza.28fv29.and.pneumococcal.28pv29.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dinsight

Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). https://meetinglibrary.asco.org/record/185977/abstract

Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). https://meetinglibrary.asco.org/record/185977/abstract

Laurence Cooper, MD, PhD on controlled, survival of subjects, and final results in IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma. All three abstracts were presented at this year’s virtual ASCO. Ziopharm will present updated clinical data from its Phase 1/2 controlled IL-12 program. Data will show clinical results of its IL-12 gene therapy, Ad+V, as a monotherapy and in combination with nivolumab for the treatment of recurrent glioblastoma (rGBM). Phase 1 data from this program have shown that treatment with Ad+V can double the median overall survival of patients with rGBM.

Laurence Cooper, MD, PhD on controlled, survival of subjects, and final results in IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma. All three abstracts were presented at this year’s virtual ASCO. Ziopharm will present updated clinical data from its Phase 1/2 controlled IL-12 program. Data will show clinical results of its IL-12 gene therapy, Ad+V, as a monotherapy and in combination with nivolumab for the treatment of recurrent glioblastoma (rGBM). Phase 1 data from this program have shown that treatment with Ad+V can double the median overall survival of patients with rGBM.

Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma

Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma

Hatem Soliman, MD of Moffitt Cancer Center @MoffittResearch discusses at the 12-chemokine gene expression score in breast cancer patients treated with neoadjuvant chemotherapy. Read here: https://meetinglibrary.asco.org/record/190814/abstract

Hatem Soliman, MD of Moffitt Cancer Center @MoffittResearch discusses at the 12-chemokine gene expression score in breast cancer patients treated with neoadjuvant chemotherapy. Read here: https://meetinglibrary.asco.org/record/190814/abstract

Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma

Laurence Cooper, MD, PhD on controlled, survival of subjects, and final results in IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma. All three abstracts were presented at this year’s virtual ASCO. Ziopharm will present updated clinical data from its Phase 1/2 controlled IL-12 program. Data will show clinical results of its IL-12 gene therapy, Ad+V, as a monotherapy and in combination with nivolumab for the treatment of recurrent glioblastoma (rGBM). Phase 1 data from this program have shown that treatment with Ad+V can double the median overall survival of patients with rGBM.

Hatem Soliman, MD of Moffitt Cancer Center @MoffittResearch discusses at the 12-chemokine gene expression score in breast cancer patients treated with neoadjuvant chemotherapy. Read here: https://meetinglibrary.asco.org/record/190814/abstract

Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses DARolutamide observationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients. Read her: https://meetinglibrary.asco.org/record/191738/abstract

Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses darolutamide and enzalutamide effects on physical and neurocognitive function and daily activity in patients with castration-resistant prostate cancer presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/191796/abstract

Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses darolutamide and enzalutamide effects on physical and neurocognitive function and daily activity in patients with castration-resistant prostate cancer presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/191796/abstract

Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): MAIC. Read here: https://meetinglibrary.asco.org/record/188306/abstract

Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): MAIC. Read here: https://meetinglibrary.asco.org/record/188306/abstract

Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the overall survival results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/187482/abstract

Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the overall survival results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/187482/abstract

Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the overall survival results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/187482/abstract

Cynthia X. Ma, MD of Washington University School of Medicine @WUSTLmed discusses neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women.

Cynthia X. Ma, MD of Washington University School of Medicine @WUSTLmed discusses neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women.

Andre Thierry, MD of University Pierre et Marie Curie @UPMC discusses pembrolizumab vs. chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: the phase 3 KEYNOTE-177 study presented at this year’s virtual ASCO. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.18_suppl.LBA4

Andre Thierry, MD of University Pierre et Marie Curie @UPMC discusses pembrolizumab vs. chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: the phase 3 KEYNOTE-177 study presented at this year’s virtual ASCO. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.18_suppl.LBA4

Brigitte C. Widemann, MD and Andrea Gross, MD of National Cancer Institute discuss selumetinib, the first medicine approved to treat paediatric patients with neurofibromatosis type 1 plexiform neurofibromas, a rare and debilitating genetic condition. More here: https://www.astrazeneca.com/media-centre/press-releases/2020/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html

Brigitte C. Widemann, MD and Andrea Gross, MD of National Cancer Institute discuss selumetinib, the first medicine approved to treat paediatric patients with neurofibromatosis type 1 plexiform neurofibromas, a rare and debilitating genetic condition. More here: https://www.astrazeneca.com/media-centre/press-releases/2020/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html

Brigitte C. Widemann, MD and Andrea Gross, MD of National Cancer Institute discuss selumetinib, the first medicine approved to treat paediatric patients with neurofibromatosis type 1 plexiform neurofibromas, a rare and debilitating genetic condition. More here: https://www.astrazeneca.com/media-centre/press-releases/2020/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html

Jeremy Warner, MD of Vanderbilt-Ingram Cancer Center @VUMC_Cancer discusses the clinical impact of COVID-19 on patients with cancer: data from the COVID-19 and Cancer Consortium (CCC19). Read here: https://meetinglibrary.asco.org/record/191968/abstract

Jeremy Warner, MD of Vanderbilt-Ingram Cancer Center @VUMC_Cancer discusses the clinical impact of COVID-19 on patients with cancer: data from the COVID-19 and Cancer Consortium (CCC19). Read here: https://meetinglibrary.asco.org/record/191968/abstract

Jeremy Warner, MD of Vanderbilt-Ingram Cancer Center @VUMC_Cancer discusses the clinical impact of COVID-19 on patients with cancer: data from the COVID-19 and Cancer Consortium (CCC19). Read here: https://meetinglibrary.asco.org/record/191968/abstract

Daniel Vorobiof, MD of Belong.Life @Belong_Life discusses real-world data of physician’s advice on BRCA genetic testing for ovary and breast cancer patients. https://meetinglibrary.asco.org/record/190666/abstract

Daniel Vorobiof, MD of Belong.Life @Belong_Life discusses real-world data of physician’s advice on BRCA genetic testing for ovary and breast cancer patients. https://meetinglibrary.asco.org/record/190666/abstract

Daniel Vorobiof, MD of Belong.Life @Belong_Life discusses real-world data of physician’s advice on BRCA genetic testing for ovary and breast cancer patients. https://meetinglibrary.asco.org/record/190666/abstract

Kevin Harrington, PhD, MBBS, of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust discusses KEYNOTE-048: progression after the next line of therapy following pembrolizumab or P plus chemotherapy vs EXTREME as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.6505

Kevin Harrington, PhD, MBBS, of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust discusses KEYNOTE-048: progression after the next line of therapy following pembrolizumab or P plus chemotherapy vs EXTREME as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.6505

Kevin Harrington, PhD, MBBS, of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust discusses KEYNOTE-048: progression after the next line of therapy following pembrolizumab or P plus chemotherapy vs EXTREME as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.6505

Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer. Read here: https://meetinglibrary.asco.org/record/191881/abstract

Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer. Read here: https://meetinglibrary.asco.org/record/191881/abstract

Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer. Read here:https://meetinglibrary.asco.org/record/191881/abstract

Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer. Read here: https://meetinglibrary.asco.org/record/191881/abstract

Jennifer Crozier, MD of Baptist Health @BaptistHealthSA discusses the FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer. Read here: https://meetinglibrary.asco.org/record/191745/abstract

Jennifer Crozier, MD of Baptist Health @BaptistHealthSA discusses the FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer. Read here: https://meetinglibrary.asco.org/record/191745/abstract

Jennifer Crozier, MD of Baptist Health @BaptistHealthSA discusses the FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer. Read here: https://meetinglibrary.asco.org/record/191745/abstract

Margaret von Mehren, MD of Fox Chase Cancer Center @FoxChaseCancer discusses the FDA Full Approval of Deciphera Pharmaceuticals’ QINLOCK for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor. Read here: https://investors.deciphera.com/news-releases/news-release-details/fda-grants-full-approval-deciphera-pharmaceuticals-qinlocktm

Margaret von Mehren, MD of Fox Chase Cancer Center @FoxChaseCancer discusses the FDA Full Approval of Deciphera Pharmaceuticals’ QINLOCK for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor. Read here: https://investors.deciphera.com/news-releases/news-release-details/fda-grants-full-approval-deciphera-pharmaceuticals-qinlocktm

Margaret von Mehren, MD of Fox Chase Cancer Center @FoxChaseCancer discusses the FDA Full Approval of Deciphera Pharmaceuticals’ QINLOCK for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor. Read here: https://investors.deciphera.com/news-releases/news-release-details/fda-grants-full-approval-deciphera-pharmaceuticals-qinlocktm

Daneng Li, MD @DanengLi of City of Hope @cityofhope on geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: a randomized controlled trial. Read here: https://meetinglibrary.asco.org/record/186710/abstract

Daneng Li, MD @DanengLi of City of Hope @cityofhope on geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: a randomized controlled trial. Read here: https://meetinglibrary.asco.org/record/186710/abstract

Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community.In this video, Dr. Li shares information on the role of immunotherapy for unresectable stage 3 non small cell lung cancer.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Jeffrey Weitzel, MD of City of Hope @cityofhope discusses clinical conundrums: developing a strategy for discerning TP53-associated chip and coherent clinical care.

Jeffrey Weitzel, MD of City of Hope @cityofhope discusses clinical conundrums: developing a strategy for discerning TP53-associated chip and coherent clinical care.

Jeffrey Weitzel, MD of City of Hope @cityofhope discusses clinical conundrums: developing a strategy for discerning TP53-associated chip and coherent clinical care. Read here: https://meetinglibrary.asco.org/record/185972/abstract

Chung-Han Lee, MD @ChungHanLee3 of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses the KEYNOTE-146/Study 111: Phase II trial of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC). Read here: https://meetinglibrary.asco.org/record/186053/abstract

Earn CME: https://www.naccme.com/program/20-hemcovid-7 In this webcast, Drs. Joseph R. Mikhael and Michael J. Satlin discuss new updates on the current understanding of the epidemiology and pathology of SARS-CoV-2 and outlines current treatment strategies, including the potential for interactions with anticancer agents. © 2020 Imedex, an HMP Company

Chung-Han Lee, MD @ChungHanLee3 of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses the KEYNOTE-146/Study 111: Phase II trial of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC). Read here: https://meetinglibrary.asco.org/record/186053/abstract

Chung-Han Lee, MD @ChungHanLee3 of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses the KEYNOTE-146/Study 111: Phase II trial of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC). Read here: https://meetinglibrary.asco.org/record/186053/abstract

Scott Tomlins, MD, PhD of Strata Oncology @StrataOncology discusses PCR-based comprehensive genomic profiling (PCR-CGP): feasibility from >20,000 tissue specimens and predicted impact on actionable biomarker identification vs. hybrid capture (H)-CGP and plasma (P)-CGP presented at this year’s virtual ASCO.

Scott Tomlins, MD, PhD of Strata Oncology @StrataOncology discusses PCR-based comprehensive genomic profiling (PCR-CGP): feasibility from >20,000 tissue specimens and predicted impact on actionable biomarker identification vs. hybrid capture (H)-CGP and plasma (P)-CGP presented at this year’s virtual ASCO. More here: https://www.strataoncology.com/asco20

Scott Tomlins, MD, PhD of Strata Oncology @StrataOncology discusses PCR-based comprehensive genomic profiling (PCR-CGP): feasibility from >20,000 tissue specimens and predicted impact on actionable biomarker identification vs. hybrid capture (H)-CGP and plasma (P)-CGP presented at this year’s virtual ASCO. More here: https://www.strataoncology.com/asco20

Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses AOEs in the ponatinib phase II PACE trial (NCT01207440) in patients with Ph+ leukemia. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.7550?af=R&

Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses AOEs in the ponatinib phase II PACE trial (NCT01207440) in patients with Ph+ leukemia. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.7550?af=R&

Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study of three ponatinib (PON) starting doses.

Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study of three ponatinib (PON) starting doses.

Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study of three ponatinib (PON) starting doses.

Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma. Read here: https://meetinglibrary.asco.org/record/185846/abstract

Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma. Read here: https://meetinglibrary.asco.org/record/185846/abstract

Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma. Read here: https://meetinglibrary.asco.org/record/185846/abstract

Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. Read here: https://meetinglibrary.asco.org/record/186874/abstract

Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. Read here: https://meetinglibrary.asco.org/record/186874/abstract

Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. Read here: https://meetinglibrary.asco.org/record/186874/abstract

Krystal Cascetta, MD of Icahn School of Medicine at Mount Sinai @IcahnMountSinai discusses oncotype recurrence scores in invasive lobular carcinomas.

Krystal Cascetta, MD of Icahn School of Medicine at Mount Sinai @IcahnMountSinai discusses oncotype recurrence scores in invasive lobular carcinomas.

Saad Z. Usmani, M.D @szusmani of Levine Cancer Institute @LevineCancer discusses the phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM). Read here: https://meetinglibrary.asco.org/record/186864/abstract

Saad Z. Usmani, M.D @szusmani of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab in the treatment of patients with MM.

Saad Z. Usmani, M.D @szusmani of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab in the treatment of patients with MM. Read here: https://www.prnewswire.com/news-releases/us-food-and-drug-administration-approves-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-a-new-subcutaneous-formulation-of-daratumumab-in-the-treatment-of-patients-with-multiple-myeloma-301051154.html

Saad Z. Usmani, M.D of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab in the treatment of patients with MM. Read here: https://www.prnewswire.com/news-releases/us-food-and-drug-administration-approves-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-a-new-subcutaneous-formulation-of-daratumumab-in-the-treatment-of-patients-with-multiple-myeloma-301051154.html

Othman Al-Sawaf, MD of University Hospital Cologne discusses fixed-duration venetoclax-obinutuzumab forpreviously untreated patients with CLL: follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial. Read here: https://meetinglibrary.asco.org/record/186845/abstract

Earn CME: https://www.naccme.com/program/20-hemcovid-6 In this webcast, Drs. Joseph R. Mikhael and Jessica K. Altman discuss best practices for addressing current and potential challenges in the diagnosis and management of myeloid malignancies during the COVID-19 pandemic. © 2020 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/20-hemcovid-5 In this webcast, Dr. Joseph R. Mikhael and patient advocate Yelak Biru discuss ways to limit patient and provider exposure to SARS-CoV-2 while effectively managing hematologic malignancies © 2020 Imedex, an HMP Company

Adrian Kilcoyne, MD of AstraZeneca @AstraZeneca discusses unprecedented results from the Phase III ADAURA trial for TAGRISSO® (osimertinib) in the adjuvant treatment of patients with Stage IB, II and IIIA epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) presented at this year’s virtual ASCO.

Adrian Kilcoyne, MD of AstraZeneca @AstraZeneca discusses unprecedented results from the Phase III ADAURA trial for TAGRISSO® (osimertinib) in the adjuvant treatment of patients with Stage IB, II and IIIA epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) presented at this year’s virtual ASCO.

Adrian Kilcoyne, MD of AstraZeneca @AstraZeneca discusses unprecedented results from the Phase III ADAURA trial for TAGRISSO® (osimertinib) in the adjuvant treatment of patients with Stage IB, II and IIIA epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) presented at this year’s virtual ASCO.

Daniel Starczynowski, PhD of Cincinnati Children’s Hospital Medical Center @Cincy_Tech Kurome Therapeutics to develop therapies targeting cancer’s ability to evade treatment. Read here: https://www.eurekalert.org/pub_releases/2020-04/c-ktt042720.php

Daniel Starczynowski, PhD of Cincinnati Children’s Hospital Medical Center @Cincy_Tech Kurome Therapeutics to develop therapies targeting cancer’s ability to evade treatment. Read here: https://www.eurekalert.org/pub_releases/2020-04/c-ktt042720.php

Othman Al-Sawaf, MD of University Hospital Cologne discusses fixed-duration venetoclax-obinutuzumab for previously untreated patients with CLL: follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial. Read here: https://meetinglibrary.asco.org/record/186845/abstract

Othman Al-Sawaf, MD of University Hospital Cologne discusses fixed-duration venetoclax-obinutuzumab for previously untreated patients with CLL: follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial. Read here: https://meetinglibrary.asco.org/record/186845/abstract

Andrew Krivoshik, MD of Astellas @AstellasUS discusses what is net for Astellas.

Andrew Krivoshik, MD of Astellas @AstellasUS discusses the long-term results of the phase III ADMIRAL trial presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/185308/abstract

Andrew Krivoshik, MD of Astellas @AstellasUS discusses the importance of the phase III PROSPER trial in the prostate cancer community presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/187453/abstract

Brian Jonas, MD, PhD of UC Davis Comprehensive Cancer Center @UCDavisHealth @ucdavis discusses timing of response to venetoclax combination treatment in older patients with AML presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/185292/abstract

Brian Jonas, MD, PhD of UC Davis Comprehensive Cancer Center @UCDavisHealth @ucdavis discusses timing of response to venetoclax combination treatment in older patients with AML presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/185292/abstract

Brian Jonas, MD, PhD of UC Davis Comprehensive Cancer Center @UCDavisHealth @ucdavis discusses timing of response to venetoclax combination treatment in older patients with AML presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/185292/abstract

Lionel Ades, MD of St. Louis Hospital discusses the phase II study of pevonedistat + azacitidine vs. A in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia presented at this year’s virtual ASCO. ______________ Results from the Phase 2 Pevonedistat-2001 trial will be presented in an oral session at ASCO. The study investigated pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk myelodysplastic syndromes (HR-MDS), higher-risk chronic myelomonocytic leukemia (HR-CMML) or low blast acute myeloid leukemia (LB-AML).These patients typically have poor prognoses as a result of limited response to available therapies. HR-MDS, in particular, has…

Lionel Ades, MD of St. Louis Hospital discusses the phase II study of pevonedistat + azacitidine vs. A in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia presented at this year’s virtual ASCO. ______________ Results from the Phase 2 Pevonedistat-2001 trial will be presented in an oral session at ASCO. The study investigated pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk myelodysplastic syndromes (HR-MDS), higher-risk chronic myelomonocytic leukemia (HR-CMML) or low blast acute myeloid leukemia (LB-AML).These patients typically have poor prognoses as a result of limited response to available therapies. HR-MDS, in particular, has…

Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced non-small cell lung cancer harboring exon 20 insertion mutations. Read here: https://meetinglibrary.asco.org/record/184802/abstract

Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced non-small cell lung cancer harboring exon 20 insertion mutations. Read here: https://meetinglibrary.asco.org/record/184802/abstract

Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced non-small cell lung cancer harboring exon 20 insertion mutations. Read here: https://meetinglibrary.asco.org/record/184802/abstract

Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced non-small cell lung cancer harboring exon 20 insertion mutations. Read here: https://meetinglibrary.asco.org/record/184802/abstract

Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced non-small cell lung cancer harboring exon 20 insertion mutations. Read here: https://meetinglibrary.asco.org/record/184802/abstract

Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results. Read here: https://meetinglibrary.asco.org/record/187437/abstract

Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results. Read here: https://meetinglibrary.asco.org/record/187437/abstract

Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results. Read here: https://meetinglibrary.asco.org/record/187437/abstract

Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results. Read here: https://meetinglibrary.asco.org/record/187437/abstract

Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results. Read here: https://meetinglibrary.asco.org/record/187437/abstract

Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results. Read here: https://meetinglibrary.asco.org/record/187437/abstract

David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T cells presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/189127/abstract

David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T cells presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/189127/abstract

David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T cells presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/189127/abstract

Ross Camidge, MD, PhD of University of Colorado Cancer Center @CUCancerCenter Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious form of lung cancer. Read here: https://www.businesswire.com/news/home/20200522005448/en/U.S.-FDA-Approves-Takeda%E2%80%99s-ALUNBRIG%C2%AE-brigatinib-First-Line

Ross Camidge, MD, PhD of University of Colorado Cancer Center @CUCancerCenter Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious form of lung cancer. Read here: https://www.businesswire.com/news/home/20200522005448/en/U.S.-FDA-Approves-Takeda%E2%80%99s-ALUNBRIG%C2%AE-brigatinib-First-Line

Ross Camidge, MD, PhD of University of Colorado Cancer Center @CUCancerCenter Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious form of lung cancer. Read here: https://www.businesswire.com/news/home/20200522005448/en/U.S.-FDA-Approves-Takeda%E2%80%99s-ALUNBRIG%C2%AE-brigatinib-First-Line  

Ross Camidge, MD, PhD on Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious form of lung cancer. Read here: https://www.businesswire.com/news/home/20200522005448/en/U.S.-FDA-Approves-Takeda%E2%80%99s-ALUNBRIG%C2%AE-brigatinib-First-Line

Edward A. Faber, DO, MS on carfilzomib, lenalidomide, and dexamethasone vs. bortezomib, lenalidomide, and dexamethasone for initial therapy of newly diagnosed multiple myeloma: results of ENDURANCE (E1A11) phase III trial. Read here:https://meetinglibrary.asco.org/record/186906/abstract  

Edward A. Faber, DO, MS on carfilzomib, lenalidomide, and dexamethasone vs. bortezomib, lenalidomide, and dexamethasone for initial therapy of newly diagnosed multiple myeloma: results of ENDURANCE (E1A11) phase III trial. Read here: https://meetinglibrary.asco.org/record/186906/abstract

Edward A. Faber, DO, MS on carfilzomib, lenalidomide, and dexamethasone vs. bortezomib, lenalidomide, and dexamethasone for initial therapy of newly diagnosed multiple myeloma: results of ENDURANCE (E1A11) phase III trial. Read here: https://meetinglibrary.asco.org/record/186906/abstract

Robert Epstein, MD, MS of Epstein Health LLC on real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey of patients with cancer. Background/Key Findings: 301 people with cancer (breast cancer = 153, lung cancer = 100, colorectal cancer = 48) who were treated with chemotherapy in the past year and experienced at least one episode of myelosuppression completed an online survey to assess the impact of chemotherapy-induced myelosuppression. Nearly nine in ten (89%) survey participants reported that myelosuppression had a moderate or major impact on their lives (moderate life impact = 49%, major life impact = 40%). Fatigue…

Robert Epstein, MD, MS of Epstein Health LLC on real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey of patients with cancer. Background/Key Findings:   301 people with cancer (breast cancer = 153, lung cancer = 100, colorectal cancer = 48) who were treated with chemotherapy in the past year and experienced at least one episode of myelosuppression completed an online survey to assess the impact of chemotherapy-induced myelosuppression. Nearly nine in ten (89%) survey participants reported that myelosuppression had a moderate or major impact on their lives (moderate life impact = 49%, major life impact = 40%).…

Robert Epstein, MD, MS of Epstein Health LLC on real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey of patients with cancer. Background/Key Findings: 301 people with cancer (breast cancer = 153, lung cancer = 100, colorectal cancer = 48) who were treated with chemotherapy in the past year and experienced at least one episode of myelosuppression completed an online survey to assess the impact of chemotherapy-induced myelosuppression. Nearly nine in ten (89%) survey participants reported that myelosuppression had a moderate or major impact on their lives (moderate life impact = 49%, major life impact = 40%). Fatigue…

Amar Gajjar, MD of St. Jude Children’s Research Hospital @StJudeResearch discusses genomics paving the way to better infant medulloblastoma therapy presented at this year’s virtual ASCO. Read here: https://ascopubs.org/doi/full/10.1200/JCO.20.00593

Amar Gajjar, MD of St. Jude Children’s Research Hospital @StJudeResearch discusses genomics paving the way to better infant medulloblastoma therapy presented at this year’s virtual ASCO. Read here: https://ascopubs.org/doi/full/10.1200/JCO.20.00593

J. Marie Suga MD @jmsuga of Kaiser Permanente Northern California discusses implementing a genomic oncology program in an integrated health care network with large scale genomic NGS testing of advanced cancers in a community setting. Read here: https://meetinglibrary.asco.org/record/190712/abstract

J. Marie Suga MD @jmsuga of Kaiser Permanente Northern California discusses implementing a genomic oncology program in an integrated health care network with large scale genomic NGS testing of advanced cancers in a community setting. Read here: https://meetinglibrary.asco.org/record/190712/abstract

J. Marie Suga MD @jmsuga of Kaiser Permanente Northern California discusses implementing a genomic oncology program in an integrated health care network with large scale genomic NGS testing of advanced cancers in a community setting. Read here: https://meetinglibrary.asco.org/record/190712/abstract